Short or long NAT for BR/LAPC (ADVANTAGE Trial)
Key facts
- Where
- Frankfurt am Main, Hamburg és Heidelberg, NémetországSee the 3 sites
- Phase
- 3. fázis
Where in Németország
- Krankenhaus Nordwest GmbHFrankfurt am Main, NémetországToborzás még nem indult
- University Medical Center Hamburg-EppendorfHamburg, NémetországToborzás még nem indult
- Universitaetsklinikum Heidelberg AöRHeidelberg, NémetországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vastra Gotalandsregionen
- Trial code
- EU 2022-502117-29-00
- Record updated
- 2026. június 22.
- Original description
To assess the optimal duration of preoperative chemotherapy before conversion surgery for patients with borderline and locally advanced pancreatic ductal adenocarcinoma in attempt to improve survivalRead full original descriptionShow less
Standard versus Prolonged Neoadjuvant (Conversion) Chemotherapy to prolong survival of patients with Borderline and Locally Advanced Pancreatic Cancer: a phase III randomized controlled trial
To assess the optimal duration of preoperative chemotherapy before conversion surgery for patients with borderline and locally advanced pancreatic ductal adenocarcinoma in attempt to improve survival
Inclusion: Borderline or locally advanced pancreatic adenocarcinoma at diagnosis according to NCCN Clinical Practice Guidelines, version 1.2022 • Histo- or cytologically confirmed adenocarcinoma • T1-4, Nx, M0 according to AJCC 8th edition • Age ≥ 18 years-of-age • ECOG 0-1 and considered fit for the planned chemotherapy and surgery • Written informed patient consent.
Exclusion: Co-morbidity precluding pancreatic surgery or chemotherapy - Sensitivity to any of the drugs in the proposed management regimens - ECOG ≥2 - neuropathy ≥ grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE), version 6 [47] - granulocyte count < 1500 per cubic millimetre (< 1,5 x 109/L) - platelet count < 100 000 per cubic millimetre (< 100 x 109/L) - serum creatinine > 1.5 UNL (upper limit normal range) - albumin <2,5 g/dl (<25 g/L) - total bilirubin >3 x ULN - ASAT (SGOT) and ALAT (SGPT) >2.5 x institutional ULN - female patients in child-bearing age not using adequate contraception, pregnant or lactating women - mental or somatic disorders which could possibly interfere with informed consent, compliance or the planned treatments - previous oncologic treatment for pancreatic adenocarcinoma within the past 5 years - Any reason according to the investigator why the patient cannot comply with the protocol or is not suitable to participate.